Abstract
Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have